Abstract
Megalin is a member of the low-density lipoprotein receptor superfamily. It has been recognized as an endocytic receptor for a large spectrum of ligands. As a consequence, megalin regulates homeostasis of many molecules and affects multiple physiological and pathophysiological functions. The renin-angiotensin system is a hormonal system. A number of studies have reported contributions of the renin-angiotensin system to atherosclerosis. There is evolving evidence that megalin is a regulator of the renin-angiotensin system, and contributes to atherosclerosis. This brief review provides contemporary insights into effects of megalin on renal functions, the renin-angiotensin system, and atherosclerosis.
Original language | English |
---|---|
Article number | 104537 |
Journal | Pharmacological Research |
Volume | 151 |
DOIs | |
State | Published - Jan 2020 |
Bibliographical note
Publisher Copyright:© 2019 Elsevier Ltd
Funding
The authors’ research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award numbers R01HL133723 and R01HL139748 and the American Heart Association SFRN in Vascular Disease ( 18SFRN33960001 ). Hisashi Sawada is supported by an American Heart Association postdoctoral fellowship ( 18POST33990468 ). Megalin-related research work is supported by R01HL139748 . The content in this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funders | Funder number |
---|---|
National Institutes of Health (NIH) | R01HL133723 |
National Heart, Lung, and Blood Institute (NHLBI) | R01HL139748 |
American Heart Association | 18POST33990468, 18SFRN33960001 |
Keywords
- Atherosclerosis
- Kidney
- Megalin
- Renin angiotensin system
ASJC Scopus subject areas
- Pharmacology